ELDN vs. BIIB
ELDN (Eledon Pharmaceuticals Inc) and BIIB (Biogen Inc.) are both stocks. Both are in the Healthcare sector — ELDN in Biotechnology, BIIB in Drug Manufacturers - General. Over the past 10 years, ELDN returned -41.85%/yr vs -2.17%/yr for BIIB. At a 0.14 correlation, their price movements are largely independent.
Performance
ELDN vs. BIIB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ELDN achieves a 155.63% return, which is significantly higher than BIIB's 18.77% return. Over the past 10 years, ELDN has underperformed BIIB with an annualized return of -41.85%, while BIIB has yielded a comparatively higher -2.17% annualized return.
ELDN
- 1D
- 0.26%
- 1M
- 8.12%
- 6M
- 102.09%
- YTD
- 155.63%
- 1Y
- 12.87%
- 3Y*
- 38.91%
- 5Y*
- -12.51%
- 10Y*
- -41.85%
BIIB
- 1D
- 4.96%
- 1M
- 4.49%
- 6M
- 12.61%
- YTD
- 18.77%
- 1Y
- 55.75%
- 3Y*
- -9.17%
- 5Y*
- -9.90%
- 10Y*
- -2.17%
ELDN vs. BIIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ELDN Eledon Pharmaceuticals Inc | 155.63% | -63.35% | 128.89% | -21.05% | -48.30% | -71.36% | 47.51% | -63.75% | -60.59% | -53.87% |
BIIB Biogen Inc. | 18.77% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
Correlation
The correlation between ELDN and BIIB is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Sep 17, 2014 | 0.14 |
Fundamentals
ELDN:
$231.40M
BIIB:
$30.86B
ELDN:
-$0.88
BIIB:
$14.01
ELDN:
$0.00
BIIB:
$9.86B
ELDN:
$0.00
BIIB:
$5.06B
ELDN:
-$84.86M
BIIB:
$2.24B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ELDN vs. BIIB — Risk / Return Rank
ELDN
BIIB
ELDN vs. BIIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ELDN | BIIB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.48 | ||
| Sortino ratioReturn per unit of downside risk | -1.59 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.28 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.19 | 3.91 | -3.72 |
| Martin ratioReturn relative to average drawdown | 0.34 | 9.76 | -9.42 |
Loading charts...
Drawdowns
ELDN vs. BIIB - Drawdown Comparison
The maximum ELDN drawdown since its inception was -99.97%, which is greater than BIIB's maximum drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for ELDN and BIIB.
Loading charts...
Drawdown Indicators
| ELDN | BIIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.97% | -89.98% | -9.99% |
Max Drawdown (1Y)Largest decline over 1 year | -68.12% | -14.34% | -53.78% |
Max Drawdown (3Y)Largest decline over 3 years | -73.77% | -59.35% | -14.42% |
Max Drawdown (5Y)Largest decline over 5 years | -86.76% | -67.59% | -19.17% |
Max Drawdown (10Y)Largest decline over 10 years | -99.87% | -72.66% | -27.21% |
Current DrawdownCurrent decline from peak | -99.90% | -56.08% | -43.82% |
Average DrawdownAverage peak-to-trough decline | -92.04% | -36.66% | -55.38% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.63% | 5.77% | +31.86% |
Volatility
ELDN vs. BIIB - Volatility Comparison
Eledon Pharmaceuticals Inc (ELDN) has a higher volatility of 17.94% compared to Biogen Inc. (BIIB) at 11.60%. This indicates that ELDN's price experiences larger fluctuations and is considered to be riskier than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ELDN | BIIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.94% | 11.60% | +6.34% |
Volatility (6M)Calculated over the trailing 6-month period | 46.37% | 25.83% | +20.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 89.85% | 34.52% | +55.33% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.52% | 34.36% | +44.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 110.19% | 41.39% | +68.80% |
Dividends
ELDN vs. BIIB - Dividend Comparison
Neither ELDN nor BIIB has paid dividends to shareholders.
Financials
ELDN vs. BIIB - Financials Comparison
This section allows you to compare key financial metrics between Eledon Pharmaceuticals Inc and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ELDN and BIIB have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ELDN has higher volatility (17.94%) compared to BIIB (11.60%). In terms of maximum drawdown, ELDN dropped -99.97% vs BIIB's -89.98%.
BIIB currently has the higher Sharpe Ratio (1.63 vs 0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ELDN and BIIB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer